BMS reports flat revenue growth for full-year 2025
The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.
Drug Development
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Everest Medicines and Micot partner on MT1013 commercialisation
PrimeGen US and DT Cloud Star sign $1.5bn merger agreement
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
CEPI and Samsung Biologics partner to boost global vaccine preparedness
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
Aquestive receives FDA CRL for Anaphylm allergic reaction treatment
